Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H3K27M-EIEs in DMG/DIPG
NCT07501156Phase 2Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2027
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in diffuse midline glioma (DMG) and diffuse intrinsic pontine glioma (DIPG), sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoint: Adverse Events at 1 month. Planned start Jun 2027; status: not yet recruiting.
02
Conditions
diffuse midline glioma (DMG)diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT07501156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07501156.